GleamWall
中文EN

ENDV ENDONOVO THERAPEUTICS, INC.

Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 1528172 · Fiscal year ends 12/31

Financial factors as of 2023-09-30 (2023Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,699.9%
TTM net income YoY-40.0%
TTM EPS YoY—
Revenue 3-yr CAGR-5.5%
Net income 3-yr CAGR—

Margins

Gross margin96.2%
Operating margin-1,023.2%
Net margin-1,722.2%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-388.5%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets2,914.6%
Debt / equity—
Current ratio0.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.14x
Accruals ratio-333.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20222022-12-31FY20212021-12-31
Income statement
Revenue$135,355$73,105
Cost of revenue$9,990$14,985
Gross profit$125,365$58,120
R&D expense—$0
Operating income-$3.26M-$2.23M
Interest expense—$941,566
Pretax income-$18.47M-$3.10M
Net income-$18.47M-$3.10M
EBITDA-$2.62M-$1.58M
EPS (basic)-0.13-0.05
EPS (diluted)—-0.05
Weighted avg. shares (diluted)—59.84M
Banking
Net interest income-$1.32M-$941,566
Balance sheet
Cash & equivalents$98$85,936
Receivables—$944
Current assets$15,822$94,855
Intangibles$1.27M$1.91M
Total assets$1.28M$2.01M
Current liabilities$33.38M$17.70M
Long-term debt$7.15M$7.26M
Total debt$7.15M$7.26M
Total liabilities$33.46M$17.78M
Shareholders' equity-$32.18M-$15.77M
Net debt$7.15M$7.17M
Shares outstanding213.23M74.50M
Cash flow statement
Operating cash flow-$678,838-$986,584
Financing cash flow$593,000$1.06M
Depreciation & amortization$646,912$648,492
Stock-based compensation$45,000$0

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.